Abstract
Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.
MeSH terms
-
Aminoglycosides / adverse effects
-
Aminoglycosides / chemistry
-
Aminoglycosides / pharmacology
-
Aminoglycosides / therapeutic use
-
Animals
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacteria / drug effects
-
Cephalosporins / adverse effects
-
Cephalosporins / chemistry
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Drug Approval*
-
Drug Resistance, Bacterial
-
Glycopeptides / adverse effects
-
Glycopeptides / chemistry
-
Glycopeptides / pharmacology
-
Glycopeptides / therapeutic use
-
Humans
-
Lipoglycopeptides
-
Pyrimidines / adverse effects
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use
-
Skin Diseases, Bacterial / drug therapy*
-
Skin Diseases, Viral / drug therapy*
-
Teicoplanin / adverse effects
-
Teicoplanin / analogs & derivatives
-
Teicoplanin / chemistry
-
Teicoplanin / pharmacology
-
Teicoplanin / therapeutic use
-
United States
-
United States Food and Drug Administration
-
beta-Lactams / adverse effects
-
beta-Lactams / chemistry
-
beta-Lactams / pharmacology
-
beta-Lactams / therapeutic use
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Cephalosporins
-
Glycopeptides
-
Lipoglycopeptides
-
Pyrimidines
-
beta-Lactams
-
iclaprim
-
ceftobiprole
-
Teicoplanin
-
dalbavancin
-
fropenem
-
oritavancin
-
telavancin